Curing peripheral nerve diseases with genetic medicine

Our mission is to turn the promise of genetic therapies into cures for people living with peripheral nerve diseases, starting with Neurofibromatosis type 1 (NF1).

180 million

people live with Peripheral Nerve Diseases

3 million

have Neurofibromatosis type 1

happy kid with parent

Bringing peripheral nerve diseases to the center

180 million

people live with Peripheral Nerve Diseases

3 million

have Neurofibromatosis type 1

We're on a mission to change that!

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce tincidunt gravida venenatis. Etiam eu consectetur ex, vitae consectetur est.

Using genetic medicines to cure

Our mission is to turn the promise of genetic therapies into cures for people living with peripheral nerve diseases, starting with Neurofibromatosis type 1 (NF1).

Leadership

Gonzalo Fernández-Miranda, PhD

Gonzalo Fernández-Miranda, PhD

CEO and co-Founder

READ MORE

Gonzalo is a serial entrepreneur in advanced therapies, having founded three companies and led operations as COO for +5 years. He achieved one exit, and earned a UK-Spain Business Award. He holds a PhD in Molecular Oncology.

Liron Elkouby, PhD

Liron Elkouby, PhD

CTO and co-Founder

READ MORE

Liron has 13+ years of experience in gene therapy, having led the development of a hemophilia gene therapy at Spark Therapeutics, later licensed to Roche. She is co-founder of Noga Therapeutics and holds a PhD in Molecular Genetics.

Kerstin Papenfuss, PhD

Kerstin Papenfuss, PhD

Board Director

READ MORE

Kerstin is Director of Pharma at Deep Science Ventures. She has built and launched over a dozen biotechs in advanced therapies. She was recently recognized as impactful female leader by the Global Leader Magazine.

Montse Montaner

Montse Montaner

Board Director

READ MORE

Montse has 25+ years of experience in pharma, having served as Chief of Sustainability at Novartis. She advises executives and boards and co-chairs the Business Advisory Council of the Children’s Tumor Foundation.

Scientific Advisory Board

Eduard Serra, PhD

Eduard Serra, PhD

NF1 Advisor

READ MORE

Principal Investigator of the Hereditary Cancer Group at IGTP with +25 years of experience in NF1 research.

Aleah Caulin, PhD

Aleah Caulin, PhD

Strategic Advisor

READ MORE

Former VP of Nonclinical at Peel Therapeutics, Aleah brings deep strategic biotech expertise and, as an NF1 mother, personal insight into the cause.

Jake Brenner, MD, PhD

Jake Brenner, MD, PhD

LNP Advisor

READ MORE

Principal Investigator at UPenn Dept of Medicine, pioneering novel LNP-based therapeutics for chronic and rare diseases.

Our values

Patients

Everything we do starts with listening to the patient. Their needs, challenges, and experiences are our greatest source of inspiration.

Innovation

We believe in bold ideas, brave solutions, and technology that creates meaningful impact.

 Focus

We know where we’re going. We focus on what truly matters to achieve results that make a significant difference.

Integrity

We act with honesty, transparency, and respect.

 Continuous Growth

Our culture is built on continuous growth, service, and joy: as individuals, as a team, and as a company